Clinical, Epidemiologic, and Therapeutic Characterization of Pediatric Psoriasis in the Costa Rican Social Security System

April 1, 2026 updated by: Daniel Barquero Orias, Caja Costarricense de Seguro Social

Epidemiological and Therapeutic Characterization Study of Psoriatic Disease in Patients Under 18 Years of Age at the Costa Rican Social Security (2018-2025)

The goal of this retrospective observational study is to characterize the clinical features, severity, comorbidities, and treatment patterns of pediatric psoriasis in patients managed in the Costa Rican Social Security System. The main questions it aims to answer are:

What are the demographic and clinical characteristics of pediatric psoriasis in Costa Rica?

What disease severity profiles, comorbidities, and treatments are observed in routine care?

All patients <18 years with confirmed psoriasis evaluated during the study period will be included. Data will be obtained from electronic health records without intervention or modification of treatment.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Pediatric psoriasis is a chronic immune-mediated inflammatory dermatosis associated with physical, psychosocial, and metabolic comorbidity burden beginning early in life. Epidemiologic and clinical data in Latin American pediatric populations remain limited, particularly in real-world care settings. This study is a retrospective observational characterization of pediatric psoriasis patients managed in the Costa Rican Social Security System. Unlike interventional trials or biologic-specific registries, it analyzes existing clinical records to describe demographic distribution, clinical subtypes, severity (PASI/BSA/DLQI or pediatric indices), comorbidities, and treatment patterns in routine practice. No therapeutic interventions or standardized follow-up are introduced. By capturing real-world pediatric psoriasis presentation and management in Costa Rica, the study provides baseline national evidence distinct from drug-specific or prospective therapeutic studies.

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Daniel E Barquero-Orias, Dermatologist
  • Phone Number: +506 83411026
  • Email: debarque@ccss.sa.cr

Study Locations

  • Costa Rica
    • Provincia de San José
      • San José, Provincia de San José, Costa Rica, 40901
        • Caja Costarricense del Seguro Social
        • Contact:
          • Daniel E Barquero-Orias, Dermatologist
          • Phone Number: +506 83411026
          • Email: debarque@ccss.sa.cr
        • Sub-Investigator:
          • Maria P Chavarria-Soto, Medical Doctor
        • Sub-Investigator:
          • Daniel E Barquero-Orias, Dermatologist
        • Sub-Investigator:
          • Benjamin Hidalgo-Matlock, Dermatologist
        • Principal Investigator:
          • Sofia Gamboa-Miranda, Dermatology Resident

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population comprises children and adolescents (<18 years) with confirmed psoriasis managed in the Costa Rican Social Security System in Costa Rica. This retrospective hospital-based cohort includes patients across pediatric age groups and psoriasis subtypes receiving routine dermatologic care. Data derived from electronic health records and reflect real-world pediatric psoriasis severity, comorbidities, and treatment patterns in specialized tertiary care without protocol-mandated interventions.

Description

Inclusion Criteria:

  • Patients younger than 18 years at the time of psoriasis diagnosis.
  • Clinical diagnosis of psoriasis established by a specialist physician (dermatologist or trained pediatrician) or by a general practitioner within the Costa Rican Social Security System (CCSS).
  • Patients evaluated in CCSS healthcare facilities between January 2018 and December 2025.
  • Clinical records containing sufficient information on key epidemiologic and therapeutic variables relevant to the study (age, sex, date of diagnosis, clinical subtype, and treatment received).

Exclusion Criteria:

  • Patients aged 18 years or older at the time of psoriasis diagnosis.
  • Clinical records incomplete or lacking sufficient information for analysis of the main study variables.
  • Patients with uncertain or unconfirmed diagnosis of psoriasis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Treatment patterns used in pediatric psoriasis in real-world clinical practice (topical, phototherapy, systemic, biologic).
Time Frame: January 2018- December 2025
January 2018- December 2025
Clinical and severity characteristics of pediatric psoriasis, including subtype and severity indices (e.g., PASI/BSA/DLQI or pediatric-adapted measures) documented in routine care.
Time Frame: January 2018- December 2025
January 2018- December 2025
Comorbidity profile in pediatric psoriasis (e.g., metabolic, cardiovascular risk factors, psoriatic arthritis).
Time Frame: January 2018- December 2025
January 2018- December 2025

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Caja Costarricense de Seguro Social

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

May 1, 2027

Study Registration Dates

First Submitted

February 28, 2026

First Submitted That Met QC Criteria

March 4, 2026

First Posted (Actual)

March 5, 2026

Study Record Updates

Last Update Posted (Actual)

April 7, 2026

Last Update Submitted That Met QC Criteria

April 1, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CEC HCG 15-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

According to the protocol

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pediatric Psoriasis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe